Susquehanna International Group, LLP Galera Therapeutics, Inc. Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 07, 2024	BUY	$0.14 - $0.27 $40,065 - $77,268	286,180 New	286,180 $40,000
Q3 2023 Nov 14, 2023	BUY	$0.17 - $3.0 $3,939 - $69,525	23,175 Added 30.75%	98,543 $17,000
Q2 2023 Aug 11, 2023	BUY	$2.5 - $3.42 $153,400 - $209,851	61,360 Added 438.04%	75,368 $235,000
Q1 2023 May 16, 2023	SELL	$1.48 - $2.68 $1,739 - $3,149	-1,175 Reduced 7.74%	14,008 $35,000
Q4 2022 Feb 14, 2023	SELL	$1.34 - $1.78 $14,596 - $19,389	-10,893 Reduced 41.77%	15,183 $22,000
Q3 2022 Nov 14, 2022	SELL	$1.15 - $2.1 $4,832 - $8,824	-4,202 Reduced 13.88%	26,076 $45,000
Q2 2022 Aug 15, 2022	SELL	$1.24 - $2.39 $36,637 - $70,614	-29,546 Reduced 49.39%	30,278 $39,000
Q1 2022 May 16, 2022	SELL	$2.01 - $4.19 $173,491 - $361,655	-86,314 Reduced 59.06%	59,824 $142,000
Q4 2021 Feb 14, 2022	BUY	$1.27 - $8.28 $185,595 - $1.21 Million	146,138 New	146,138 $671,000

961K

Ticker GRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 26,821,600
Market Cap $1.34M
Description
Galera Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for the transformation of radiotherapy in cancer. The company's lead product candidate is avasopasem manganese (GC4419), a small molecule superoxide dismutase mimetic, which has completed Phase III clinical tria...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.